Hyeung Ju Park

Dr. Hyeung Ju Park


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in Clinical and Translational Medicine
Verified
Journal Article
Open access
JBJung Eun Baik
Jung Eun Baik
HPHyeung Ju Park
Hyeung Ju Park
RKRaghu P. Kataru
Raghu P. Kataru
ISIra L. Savetsky
Ira L. Savetsky
CLCatherine L. Ly
Catherine L. Ly
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
Background: Secondary lymphedema is a common complication of cancer treatment, and previous studies have shown that the expression of transforming growth factor‐beta 1 (TGF‐β1), a pro‐fibrotic and anti‐lymphangiogenic growth factor, is increased in this disease. Inhibition of TGF‐β1 decreases the severity of the disease in mouse models; however, the mechanisms that regulate this improvement remain unknown.Methods: Expression of TGF‐β1 and extracellular matrix molecules (ECM) was assessed in biopsy specimens from patients with unilateral breast cancer‐related lymphedema (BCRL). The effects of TGF‐β1 inhibition using neutralizing antibodies or a topical formulation of pirfenidone (PFD) were analyzed in mouse models of lymphedema. We also assessed the direct effects of TGF‐β1 on lymphatic endothelial cells (LECs) using transgenic mice that expressed a dominant‐negative TGF‐β receptor selectively on LECs (LECDN‐RII).Results: The expression of TGF‐β1 and ECM molecules is significantly increased in BCRL skin biopsies. Inhibition of TGF‐β1 in mouse models of lymphedema using neutralizing antibodies or with topical PFD decreased ECM deposition, increased the formation of collateral lymphatics, and inhibited infiltration of T cells. In vitro studies showed that TGF‐β1 in lymphedematous tissues increases fibroblast, lymphatic endothelial cell (LEC), and lymphatic smooth muscle cell stiffness. Knockdown of TGF‐β1 responsiveness in LECDN‐RII resulted in increased lymphangiogenesis and collateral lymphatic formation; however, ECM deposition and fibrosis persisted, and the severity of lymphedema was indistinguishable from controls.Conclusions: Our results show that TGF‐β1 is an essential regulator of ECM deposition in secondary lymphedema and that inhibition of this response is a promising means of treating lymphedema.

18 September 2021 in Biology
Verified
Journal Article
Open access
PDF file
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
HPHyeung Ju Park
Hyeung Ju Park
RKRaghu P Kataru
Raghu P Kataru
JBJacqueline Bromberg
Jacqueline Bromberg
MCMichelle Coriddi
Michelle Coriddi
JDJoseph Dayan
Joseph Dayan
Recent studies suggest that Th2 cells play a key role in the pathology of secondary lymphedema by elaborating cytokines such as IL4 and IL13. The aim of this study was to test the efficacy of QBX258, a monoclonal IL4/IL13 neutralizing antibody, in women with breast cancer–related lymphedema (BCRL). We enrolled nine women with unilateral stage I/II BCRL and treated them once monthly with intravenous infusions of QBX258 for 4 months. We measured limb volumes, bioimpedance, and skin tonometry, and analyzed the quality of life (QOL) using a validated lymphedema questionnaire (Upper Limb Lymphedema 27, ULL-27) before treatment, immediately after treatment, and 4 months following treatment withdrawal. We also obtained 5 mm skin biopsies from the normal and lymphedematous limbs before and after treatment. Treatment was well-tolerated; however, one patient with a history of cellulitis developed cellulitis during the trial and was excluded from further analysis. We found no differences in limb volumes or bioimpedance measurements after drug treatment. However, QBX258 treatment improved skin stiffness (p < 0.001) and improved QOL measurements (Physical p < 0.05, Social p = 0.01). These improvements returned to baseline after treatment withdrawal. Histologically, treatment decreased epidermal thickness, the number of proliferating keratinocytes, type III collagen deposition, infiltration of mast cells, and the expression of Th2-inducing cytokines in the lymphedematous skin. Our limited study suggests that immunotherapy against Th2 cytokines may improve skin changes and QOL of women with BCRL. This treatment appears to be less effective for decreasing limb volumes; however, additional studies are needed.

28 December 2023 in Cells
Verified
Journal Article
Open access
PDF file
KKKevin Kuonqui
Kevin Kuonqui
ACAdana-Christine Campbell
Adana-Christine Campbell
ASAnanta Sarker
Ananta Sarker
ARArielle Roberts
Arielle Roberts
BPBracha L. Pollack
Bracha L. Pollack
RKRaghu P Kataru
Raghu P Kataru
Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR3), a receptor tyrosine kinase encoded by the FLT4 gene, plays a significant role in the morphogenesis and maintenance of lymphatic vessels. Under both normal and pathologic conditions, VEGF-C and VEGF-D bind VEGFR3 on the surface of lymphatic endothelial cells (LECs) and induce lymphatic proliferation, migration, and survival by activating intracellular PI3K-Akt and MAPK-ERK signaling pathways. Impaired lymphatic function and VEGFR3 signaling has been linked with a myriad of commonly encountered clinical conditions. This review provides a brief overview of intracellular VEGFR3 signaling in LECs and explores examples of dysregulated VEGFR3 signaling in various disease states, including (1) lymphedema, (2) tumor growth and metastasis, (3) obesity and metabolic syndrome, (4) organ transplant rejection, and (5) autoimmune disorders. A more complete understanding of the molecular mechanisms underlying the lymphatic pathology of each disease will allow for the development of novel strategies to treat these chronic and often debilitating illnesses.

13 March 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
DDDragos C. Dasoveanu
Dragos C. Dasoveanu
HPHyeung Ju Park
Hyeung Ju Park
CLCatherine L. Ly
Catherine L. Ly
WSWilliam D. Shipman
William D. Shipman
SCSusan Chyou
Susan Chyou
TLTheresa T. Lu
Theresa T. Lu
Nonhematopoietic stromal cells in lymph nodes such as fibroblastic reticular cells (FRCs) can support the survival of plasmablasts and plasma cells [together, antibody-forming cells (AFCs)]. However, a regulatory function for the stromal compartment in AFC accumulation has not been appreciated. Here, we show that chemokine ligand 2 (CCL2)–expressing stromal cells limit AFC survival. FRCs express high levels of CCL2 in vessel-rich areas of the T cell zone and the medulla, where AFCs are located. FRC CCL2 is up-regulated during AFC accumulation, and we use lymph node transplantation to show that CCL2 deficiency in BP3+ FRCs and lymphatic endothelial cells increases AFC survival without affecting B or germinal center cell numbers. Monocytes are key expressers of the CCL2 receptor CCR2, as monocyte depletion and transfer late in AFC responses increases and decreases AFC accumulation, respectively. Monocytes express reactive oxygen species (ROS) in an NADPH oxidase 2 (NOX2)–dependent manner, and NOX2-deficient monocytes fail to reduce AFC numbers. Stromal CCL2 modulates both monocyte accumulation and ROS production, and is regulated, in part, by manipulations that modulate vascular permeability. Together, our results reveal that the lymph node stromal compartment, by influencing monocyte accumulation and functional phenotype, has a regulatory role in AFC survival. Our results further suggest a role for inflammation-induced vascular activity in tuning the lymph node microenvironment. The understanding of stromal-mediated AFC regulation in vessel-rich environments could potentially be harnessed to control antibody-mediated autoimmunity.

1 June 2023 in Current Breast Cancer Reports
Verified
Journal Article
Closed access
PDF file
SBStav Brown
Stav Brown
ACAdana C. Campbell
Adana C. Campbell
KKKevin Kuonqui
Kevin Kuonqui
ASAnanta Sarker
Ananta Sarker
HPHyeung Ju Park
Hyeung Ju Park
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara

10 August 2021 in Science Signaling
Verified
Journal Article
Closed access
RKRaghu P Kataru
Raghu P Kataru
JBJung Eun Baik
Jung Eun Baik
HPHyeung Ju Park
Hyeung Ju Park
CLCatherine Ly
Catherine Ly
JSJinyeon Shin
Jinyeon Shin
BMBabak J. Mehrara
Babak J. Mehrara
The lymphatic network can be expanded in size and function by enhancing intracellular VEGFR3 signaling.